Covid-19 and Vaccine Q&A
Saturday, May 15 | 10:00am - 11:00am PDT
Dr. Andrew Leavitt, co-director of the UCSF Hemophilia Treatment Center
Having technical issues with zoom? Call into the session and use the meeting ID: 828 1483 3692
+1 669 900 9128 US (San Jose)
+1 346 248 7799 US (Houston)
+1 253 215 8782 US (Tacoma)
+1 312 626 6799 US (Chicago)
+1 646 558 8656 US (New York)
+1 301 715 8592 US (Washington DC)
Find your local number: https://us02web.zoom.us/u/kcgMX6H3vN
Dr. Andrew Leavitt is director of UCSF's program for noncancerous blood disorders as well as co-director of the UCSF Hemophilia Treatment Center. He cares for patients with nonmalignant blood diseases, including bleeding disorders (such as hemophilia and von Willebrand disease), platelet function disorders, disorders of insufficient platelets, venous thromboembolic disorders (which involve blood clots), neutropenia (reduced numbers of the white blood cells called neutrophils) and anemia.
Leavitt is medical director of UCSF's laboratory for blood and marrow transplant research. He is internationally known for his studies of the development of megakaryocytes, large cells in the bone marrow that divide to produce blood platelets. His research also focuses on improving treatment and outcomes for patients with venous thromboembolic diseases.
Leavitt obtained his medical degree at Harvard Medical School. He completed a residency in internal medicine and served as chief resident at the University of Michigan. At UCSF, he completed a fellowship in hematology and oncology, followed by a fellowship in transfusion medicine. He joined the UCSF faculty in 1992.
Leavitt has served on the editorial boards of Blood and the Journal of Clinical Investigation. He currently serves on the editorial board of the Journal of Clinical and Translational Science.
